Diabetic Retinopathy: Early Molecular Signs Offer Hope for Vision Protection
Diabetic retinopathy is a leading cause of vision loss in people with diabetes. However, new avenues for protecting vision may be on the horizon, thanks to research identifying early molecular signals of inflammation and vascular damage. This could allow for earlier intervention and potentially prevent irreversible vision loss.
Early Signs of Damage
A study led by scientists at the Unidad de Investigación Oftalmológica “Santiago Grisolía” de FISABIO, with support from the Red de Enfermedades Inflamatorias (RICORS-REI), reveals that diabetic retinopathy exhibits clear signs of inflammation and vascular damage even in its earliest stages – before visible complications appear in the eye.
analysing the Eye’s Fluid
Researchers analyzed the humor acuoso, a clear fluid in the front of the eye and found that patients with early-stage diabetic retinopathy had higher levels of molecules linked to chronic inflammation and blood vessel changes compared to diabetic patients without retinopathy and control groups. These molecular changes are detectable even when a standard eye exam shows no signs of disease.
This discovery suggests these molecules could serve as preventative diagnostic biomarkers, allowing doctors to identify patients at higher risk of disease progression before retinal lesions develop.
Key Molecular Markers
The study identified several key biomarkers, including various interleucins (IL), elevated levels of VEGF, GM-CSF, and several chemokines. Increased presence of these mediators indicates a localized inflammatory response within the eye, even in the early phases of the disease. Specifically, interleukins like IL-1β and IL-6, which act as messengers in the immune system and are associated with chronic inflammation, were detected. Elevated levels of VEGF, a molecule involved in abnormal blood vessel formation, GM-CSF, which stimulates immune cells, and chemokines, proteins that attract inflammatory cells like MCP-1 or IP-10, were also found.
The study suggests this molecular profile could be a valuable tool for early diagnosis, identifying patients likely to experience progression before visible retinal damage occurs. It also opens the door to new therapies targeting these molecules to slow vascular damage and preserve vision.
A New Understanding of the Disease
“This discovery allows us to advance the molecular diagnosis of diabetic retinopathy and even personalize therapeutic actions, in order to prevent visual loss in diabetic patients,” explains Dra. Maria Dolores Pinazo Durán, director of the Unidad de Investigación en Oftalmología del FISABIO and member of the Red de Enfermedades Inflamatorias.
The research reinforces the understanding that diabetic retinopathy isn’t solely a vascular disease, but a complex process where inflammation plays a key role from the beginning. This inflammatory environment can contribute to progressive retinal damage and increase the risk of irreversible vision complications.
Currently available treatments could potentially be supplemented with therapies aimed at controlling inflammation, particularly in the early stages, when preventing further damage is most effective.
Frequently Asked Questions
What is diabetic retinopathy?
Diabetic retinopathy is an eye complication associated with diabetes mellitus type 2, characterized by high blood glucose levels. It damages the small blood vessels in the retina, the light-sensitive tissue at the back of the eye.
When is diabetic retinopathy most dangerous?
In its early stages, known as non-proliferative diabetic retinopathy (NPDR), the disease can progress silently without visual symptoms, making early detection crucial.
What molecules were identified as biomarkers in this study?
Researchers identified several interleucins (IL), elevated levels of VEGF, GM-CSF, and various chemokines as potential biomarkers for early detection of diabetic retinopathy.
Given these findings, how might early detection of these molecular markers change the way diabetic retinopathy is managed in the future?